Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy
Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicit...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Brys, Adam K. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Umfang: |
13 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling - Reisinger, S. ELSEVIER, 2018, research reviews and patent abstracts, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:34 ; year:2016 ; number:5 ; pages:565-577 ; extent:13 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.biotechadv.2016.01.004 |
|---|
| Katalog-ID: |
ELV029832136 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029832136 | ||
| 003 | DE-627 | ||
| 005 | 20230625175626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biotechadv.2016.01.004 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016013000026.pica |
| 035 | |a (DE-627)ELV029832136 | ||
| 035 | |a (ELSEVIER)S0734-9750(16)30003-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Brys, Adam K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 13 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. | ||
| 520 | |a Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. | ||
| 700 | 1 | |a Gowda, Raghavendra |4 oth | |
| 700 | 1 | |a Loriaux, Daniel B. |4 oth | |
| 700 | 1 | |a Robertson, Gavin P. |4 oth | |
| 700 | 1 | |a Mosca, Paul J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science Publ |a Reisinger, S. ELSEVIER |t Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling |d 2018 |d research reviews and patent abstracts |g Amsterdam |w (DE-627)ELV000162000 |
| 773 | 1 | 8 | |g volume:34 |g year:2016 |g number:5 |g pages:565-577 |g extent:13 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.biotechadv.2016.01.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 34 |j 2016 |e 5 |h 565-577 |g 13 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
a k b ak akb |
|---|---|
| matchkey_str |
brysadamkgowdaraghavendraloriauxdanielbr:2016----:aoehooyaesrtgefrobtntxctadei |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
51.00 51.32 |
| publishDate |
2016 |
| allfields |
10.1016/j.biotechadv.2016.01.004 doi GBVA2016013000026.pica (DE-627)ELV029832136 (ELSEVIER)S0734-9750(16)30003-9 DE-627 ger DE-627 rakwb eng 570 570 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Brys, Adam K. verfasserin aut Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Gowda, Raghavendra oth Loriaux, Daniel B. oth Robertson, Gavin P. oth Mosca, Paul J. oth Enthalten in Elsevier Science Publ Reisinger, S. ELSEVIER Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling 2018 research reviews and patent abstracts Amsterdam (DE-627)ELV000162000 volume:34 year:2016 number:5 pages:565-577 extent:13 https://doi.org/10.1016/j.biotechadv.2016.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 34 2016 5 565-577 13 045F 570 |
| spelling |
10.1016/j.biotechadv.2016.01.004 doi GBVA2016013000026.pica (DE-627)ELV029832136 (ELSEVIER)S0734-9750(16)30003-9 DE-627 ger DE-627 rakwb eng 570 570 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Brys, Adam K. verfasserin aut Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Gowda, Raghavendra oth Loriaux, Daniel B. oth Robertson, Gavin P. oth Mosca, Paul J. oth Enthalten in Elsevier Science Publ Reisinger, S. ELSEVIER Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling 2018 research reviews and patent abstracts Amsterdam (DE-627)ELV000162000 volume:34 year:2016 number:5 pages:565-577 extent:13 https://doi.org/10.1016/j.biotechadv.2016.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 34 2016 5 565-577 13 045F 570 |
| allfields_unstemmed |
10.1016/j.biotechadv.2016.01.004 doi GBVA2016013000026.pica (DE-627)ELV029832136 (ELSEVIER)S0734-9750(16)30003-9 DE-627 ger DE-627 rakwb eng 570 570 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Brys, Adam K. verfasserin aut Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Gowda, Raghavendra oth Loriaux, Daniel B. oth Robertson, Gavin P. oth Mosca, Paul J. oth Enthalten in Elsevier Science Publ Reisinger, S. ELSEVIER Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling 2018 research reviews and patent abstracts Amsterdam (DE-627)ELV000162000 volume:34 year:2016 number:5 pages:565-577 extent:13 https://doi.org/10.1016/j.biotechadv.2016.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 34 2016 5 565-577 13 045F 570 |
| allfieldsGer |
10.1016/j.biotechadv.2016.01.004 doi GBVA2016013000026.pica (DE-627)ELV029832136 (ELSEVIER)S0734-9750(16)30003-9 DE-627 ger DE-627 rakwb eng 570 570 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Brys, Adam K. verfasserin aut Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Gowda, Raghavendra oth Loriaux, Daniel B. oth Robertson, Gavin P. oth Mosca, Paul J. oth Enthalten in Elsevier Science Publ Reisinger, S. ELSEVIER Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling 2018 research reviews and patent abstracts Amsterdam (DE-627)ELV000162000 volume:34 year:2016 number:5 pages:565-577 extent:13 https://doi.org/10.1016/j.biotechadv.2016.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 34 2016 5 565-577 13 045F 570 |
| allfieldsSound |
10.1016/j.biotechadv.2016.01.004 doi GBVA2016013000026.pica (DE-627)ELV029832136 (ELSEVIER)S0734-9750(16)30003-9 DE-627 ger DE-627 rakwb eng 570 570 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Brys, Adam K. verfasserin aut Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. Gowda, Raghavendra oth Loriaux, Daniel B. oth Robertson, Gavin P. oth Mosca, Paul J. oth Enthalten in Elsevier Science Publ Reisinger, S. ELSEVIER Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling 2018 research reviews and patent abstracts Amsterdam (DE-627)ELV000162000 volume:34 year:2016 number:5 pages:565-577 extent:13 https://doi.org/10.1016/j.biotechadv.2016.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 34 2016 5 565-577 13 045F 570 |
| language |
English |
| source |
Enthalten in Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling Amsterdam volume:34 year:2016 number:5 pages:565-577 extent:13 |
| sourceStr |
Enthalten in Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling Amsterdam volume:34 year:2016 number:5 pages:565-577 extent:13 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling |
| authorswithroles_txt_mv |
Brys, Adam K. @@aut@@ Gowda, Raghavendra @@oth@@ Loriaux, Daniel B. @@oth@@ Robertson, Gavin P. @@oth@@ Mosca, Paul J. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000162000 |
| dewey-sort |
3570 |
| id |
ELV029832136 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029832136</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625175626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biotechadv.2016.01.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016013000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029832136</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0734-9750(16)30003-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brys, Adam K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gowda, Raghavendra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loriaux, Daniel B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robertson, Gavin P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Paul J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science Publ</subfield><subfield code="a">Reisinger, S. ELSEVIER</subfield><subfield code="t">Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling</subfield><subfield code="d">2018</subfield><subfield code="d">research reviews and patent abstracts</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV000162000</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:565-577</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biotechadv.2016.01.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2016</subfield><subfield code="e">5</subfield><subfield code="h">565-577</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Brys, Adam K. |
| spellingShingle |
Brys, Adam K. ddc 570 ddc 600 bkl 51.00 bkl 51.32 Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| authorStr |
Brys, Adam K. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000162000 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 570 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| topic |
ddc 570 ddc 600 bkl 51.00 bkl 51.32 |
| topic_unstemmed |
ddc 570 ddc 600 bkl 51.00 bkl 51.32 |
| topic_browse |
ddc 570 ddc 600 bkl 51.00 bkl 51.32 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r g rg d b l db dbl g p r gp gpr p j m pj pjm |
| hierarchy_parent_title |
Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling |
| hierarchy_parent_id |
ELV000162000 |
| dewey-tens |
570 - Life sciences; biology 600 - Technology 690 - Building & construction |
| hierarchy_top_title |
Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000162000 |
| title |
Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| ctrlnum |
(DE-627)ELV029832136 (ELSEVIER)S0734-9750(16)30003-9 |
| title_full |
Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| author_sort |
Brys, Adam K. |
| journal |
Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling |
| journalStr |
Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
565 |
| author_browse |
Brys, Adam K. |
| container_volume |
34 |
| physical |
13 |
| class |
570 570 DE-600 600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Brys, Adam K. |
| doi_str_mv |
10.1016/j.biotechadv.2016.01.004 |
| dewey-full |
570 600 690 |
| title_sort |
nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| title_auth |
Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| abstract |
Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. |
| abstractGer |
Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. |
| abstract_unstemmed |
Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
5 |
| title_short |
Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy |
| url |
https://doi.org/10.1016/j.biotechadv.2016.01.004 |
| remote_bool |
true |
| author2 |
Gowda, Raghavendra Loriaux, Daniel B. Robertson, Gavin P. Mosca, Paul J. |
| author2Str |
Gowda, Raghavendra Loriaux, Daniel B. Robertson, Gavin P. Mosca, Paul J. |
| ppnlink |
ELV000162000 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.biotechadv.2016.01.004 |
| up_date |
2024-07-06T22:29:27.054Z |
| _version_ |
1803870501134663680 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029832136</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625175626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biotechadv.2016.01.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016013000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029832136</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0734-9750(16)30003-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brys, Adam K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gowda, Raghavendra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loriaux, Daniel B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robertson, Gavin P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Paul J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science Publ</subfield><subfield code="a">Reisinger, S. ELSEVIER</subfield><subfield code="t">Strain energy contributions on the bainitic phase transformation in a CrMoV steel during continuous cooling</subfield><subfield code="d">2018</subfield><subfield code="d">research reviews and patent abstracts</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV000162000</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:565-577</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biotechadv.2016.01.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2016</subfield><subfield code="e">5</subfield><subfield code="h">565-577</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.3994904 |